Gailina Liew is a non-executive director, entrepreneur and retired listed company executive with more than 20 years experience in commercialising personalised medicine and bioinformatic technologies, establishing strategic alliances in North America and Asia, managing public-private partnerships, and translating ideas into viable business opportunities.
As an entrepreneur, Gailina took a novel genomic technology and established a molecular diagnostics company that successfully commercialised the world’s first blood test for colorectal cancer, and lead the company’s transformation from a start-up to a Toronto Stock Exchange listed company. Previous roles include in-house legal counsel for a public-private venture capital fund, management consultant, and an adjudicative member of a provincial tribunal to consider claims from alleged victims of crime.
In the last few years, Gailina has devoted her time to the governance of various private and public bodies. Prior to moving to Jersey in 2015, Gailina served as Board Chair for a regional centre of innovation and entrepreneurship in Canada’s York Region, a technology business accelerator and incubator supporting a highly diverse group of 14 urban-rural municipalities with a population of over one million people that is credited with supporting the growth of over 1,000 business technology start-ups to date.
Gailina holds a BSc in Molecular Genetics & Molecular Biology (University of Toronto), a LLB (Western University), an MBA (Kellogg School of Management, Northwestern University & Schulich School of Business, York University), and is a certified adjudicator (Society of Ontario Adjudicators and Regulators & Osgoode Hall Law School, York University).